Nanoform Finland

Historical price data

Nanoform Finland is a public biotech company specializing in nanonizing active pharmaceutical ingredients (APIs) to overcome solubility challenges, a major hurdle in drug development. Its core CESS® technology creates nano-sized particles without harsh chemicals, enhancing drug absorption and enabling new delivery routes. The company operates a client-centric business model, partnering with drug developers globally to improve existing compounds and rescue promising molecules that failed due to poor solubility.

Proprietary Controlled Expansion of Supercritical Solutions (CESS®) technology that uses supercritical CO2 to create nano-sized drug particles, improving solubility and bioavailability without harsh solvents.

1 drug in pipeline

Total raised: $74.2M

Competes with other particle engineering firms (e.g., Jazz Pharma's NanoCrystal®) and CDMOs offering solubility solutions. Nanoform differentiates with its green, solvent-free CESS® technology, precise particle control, and a dedicated focus on expanding into nanoforming biologics, which is a less crowded, high-potential segment.